Goodman’s Oxford Business Park strengthens pharmaceutical and healthcare occupancy with new lease to Oxford BioDynamics

20 Jan 2015

Global integrated property group Goodman has secured a 3,795 sq ft letting with healthcare service company Oxford BioDynamics at Oxford Business Park.

Oxford BioDynamics Limited (OBD) is a world leading epigenetic biomarker development company which develops and produces a technology based on epigenetics of gene expression. The business will be expanding its laboratory operations from its current headquarters at Beaumont Street (Oxford), to occupy a mix of both office and laboratory space in the first floor of Building 7600 under a new 10 year lease.

Goodman, which owns, develops and manages Oxford Business Park, hopes to welcome Oxford BioDynamics to its new premises following completion of the fit out works in March.

The new letting adds to a growing number of businesses within the pharmaceutical, biotech and healthcare sectors relocating to Oxford Business Park. These include Zinc Ahead, the world’s leading provider of compliance solutions for the life sciences industry; LifeCell, a pioneer in the science of regenerative medicine, and; EUSA Pharma, an international division of Jazz Pharmaceuticals.

In 2013, Zinc Ahead extended the total space it leased at Oxford Business from 5,818 sq ft to 10,703 sq ft, to accommodate its rapidly expanding team following impressive business growth. While more recently, EUSA Pharma relocated to the 14,130 sq ft Wing B of Spires House on Oxford Business Park, in order to facilitate its ambitious growth plans.

James Raven, Development Director, Goodman UK Business Parks, said: 

“We warmly welcome Oxford BioDynamics to the growing cluster of pharmaceutical and healthcare solutions providers at the Park. Oxford prides itself on being the UK’s intellectual capital and we’re delighted that Oxford BioDynamics will conduct its pioneering work within our business park. Over the years we have seen several businesses within this sector flourish and expand their operations, and we are confident Oxford BioDynamics will be equally successful.”

Christian Hoyer Millar, CEO of Oxford BioDynamics Limited, said: 

“Oxford Biodynamics is expanding its laboratory capacity both in Oxford and in Asia in order to service the increasing demand for its Episwitch biomarker platform from Pharma worldwide. What attracted us to the Oxford Business Park was the city centre location and its proximity to our roots in Oxford where the majority of our employees are based.” 

Oxford Business Park is well placed for access to Oxford city centre and the wider South East and Midlands regions. It is home to a flourishing local business network of over 70 companies, including household names, Oxfam, BT and Centrica, whose new 100,000 square foot headquarters was recently completed at the Park.

VSL and Partners advised Oxford BioDynamics on the letting.